An Open-Label, Investigator Study to Evaluate the Short-term (4 Weeks) Effects of TOLCAPONE on Transthyretin Stability in Subjects With Leptomeningeal TTR Amyloidosis (ATTR) With and Without CNS Manifestations
Phase of Trial: Phase 0
Latest Information Update: 04 Dec 2018
At a glance
- Drugs Tolcapone (Primary)
- Indications Amyloidosis
- Focus Pharmacodynamics; Proof of concept
- 11 Oct 2018 Planned End Date changed from 1 Jan 2019 to 1 Feb 2019.
- 11 Oct 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Feb 2019.
- 12 Sep 2018 Status changed from not yet recruiting to recruiting.